Product Description

Anti VEGF Biosimilar Injection

Anti VEGF Biosimilar Injection: Exudative or “wet” age-related macular degeneration (AMD) remains one of the leading causes of rapid, irreversible central vision loss among aging populations worldwide. BioCornea Tech Global, a premier biomedical innovator based in South Korea, proudly introduces our high-performance Anti-VEGF Biosimilar Injection Formulation (Per Vial). Specifically engineered to deliver targeted anti-angiogenic therapy, this advanced intravitreal solution plays a critical role in standard-of-care protocols. By binding to and neutralizing Vascular Endothelial Growth Factor (VEGF) proteins within the eye, it actively stops the underlying biological mechanisms that drive pathological neovascularization, offering hope and visual stability to millions of patients suffering from retinal vascular diseases.

The progression of wet macular degeneration is characterized by the abnormal growth of fragile, leaky blood vessels beneath the macula. These vessels bleed and exude fluid into the retinal layers, causing severe distortion and scarring. Our next-generation biosimilar formulation works at a molecular level to suppress this destructive vascular growth, promote the regression of existing abnormal vessels, and reduce macular edema. Developed with strict adherence to international biometric standards, each sterile vial delivers identical clinical efficacy, safety profiles, and immunogenicity profiles compared to reference biologics, ensuring that retina specialists can confidently implement a highly affordable yet top-tier therapeutic regimen.

As globally recognized specialists in advanced eye care, BioCornea Tech Global does not just engineer diagnostics—we revolutionize the entire spectrum of vision therapeutics. Our extensive biomedical portfolio encompasses breakthrough 3D-bioprinted ocular implants, custom specialized ocular prosthetics, next-generation advanced intraocular lenses (IOLs), comprehensive ophthalmic diagnostic imaging systems, and cutting-edge regenerative ophthalmic therapeutics & solutions. This multidisciplinary framework enables our South Korean research and manufacturing complexes to build highly sophisticated medical compounds that successfully address all eye-related issues.

We firmly believe that sight-saving biologic therapies should be accessible to hospitals and clinics across every border without prohibitive financial barriers. That is why BioCornea Tech Global operates a robust, world-wide distribution network and strict cold-chain logistics infrastructure, allowing us to solve complex visual impairments globally. We deliver our Anti-VEGF vials directly to retinal clinics, major health networks, and international distributors across every continent.

Whether you are a vitreoretinal surgeon seeking reliable biologic formulations or an international medical distributor looking to expand your therapeutic portfolio with world-class South Korean innovations, our Anti-VEGF biosimilar represents the peak of modern retinal care. Partner with a truly global leader in ocular health. To explore clinical validation studies, structural documentation, or international ordering guidelines, visit our website at biocorneatech.com or connect with our international logistics desk via email at info@biocorneatech.com. Let us help you protect and preserve clear vision worldwide. check out our ophthalmic-product-portfolio HERE